Faruqi& Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AVEO Pharmaceuticals, Inc.. Specifically, the investigation focuses on whether the Company failed to disclose that: the FDA had recommended to the Company that it conduct an additional Phase III trial due to adverse trends in the Company's fi
However, Ventrus issued a press release on June 25, 2012 announcing that VEN 309 failed its Phase III trial, causing the Company to abandon further development of VEN 309, including any further attempt to obtain FDA approval. In response to this news, the price of Ventrus common stock plummeted over 50%, to $5.02 per share, on June 25, 2012. You ca
May 18 A Santa Fe County magistrate on Friday tossed out a man's claim for damages against a doctor who refused to give him a prescription for the anti-anxiety drug Xanax. Christopher Fletcher at the Santa Fe Family Practice on Dec. 26, seeking a three-times-a-day prescription for the drug due to stress that was aggravating his diabetes and high
May 18 RALEIGH Indian pharmaceutical maker Ranbaxy will pay $8.74 million to North Carolina as part of an overall $500 million settlement reached with several states and the federal government for selling generic drugs that didn't meet quality standards. The agreement settles allegations that Ranbaxy sold drugs that fell below the quality, puri
By a News Reporter-Staff News Editor at Marketing Weekly News Valeant Consumer Products, a division of Valeant Pharmaceuticals North America LLC, multinational and specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products, has recognized the size and growth of the U.S. Caladryl is a familiar
May 18 Ohio Attorney General Mike DeWine announced that Ohio has joined with other states and the federal government in a $500 million dollar settlement to resolve civil and criminal allegations against a pharmaceutical manufacturer in India. Investigators said Ranbaxy, a generic pharmaceutical manufacturer based in Gurgaon, India, introduced...
Vortioxetine clinical phase III data show significant improvement in symptoms of major depression Takeda and Lundbeck present results from pivotal phase III clinical trials with vortioxetine, an investigational compound for major depression First presentation of results from four pivotal clinical studies of doses of up to 20 mg/day Clinical s
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors DAO, James; DAO, Tom C.S.; TONG, David D.; WILSON, Leslie; JORDAN, Mary Ann; GERWICK, William, filed on April 12, 2012, was made available online on May 2, 2013, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Other ris
*Galapagos to fund and complete Phase 2 study; AbbVie to pay Galapagos $50 million upon successful completion, expected in 2015. Galapagos NV and AbbVie announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designe
Aeolus Pharmaceuticals, Inc., a biotechnology company leveraging significant government funding to develop a platform of novel compounds to protect against radiological and chemical threats and for use in oncology, announced the appointment of John M. Clerici, Mitchell D. Kaye, and Jeffrey A. Scott, M.D., to its board of directors and accepted the
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the Company's President and CEO, Michael Heffernan, will present the Company's corporate overview on Monday, May 20, 2013 at 1:30pm EDT at the UBS Global Health Care Conference. The conference will be held at the Sheraton New York Hotel in New York City.
The Ranking Democratic Member of the House Oversight& Government Reform Committee issued the following news release:. Elijah E. Cummings, Ranking Member of the House Committee on Oversight and Government Reform, introduced legislation to address "gray market" drug companies that are taking advantage of the national drug shortage crisis to charge ex
SYDNEY and BEDMINSTER, N.J., May 17, 2013/ PRNewswire/ QRxPharma Limited announced today the US Food and Drug Administration has set 17 July 2013 as the date of the Advisory Committee meeting to consider the Company's resubmitted MOXDUO New Drug Application. The Advisory Committee is open to the public and will be held from 8.00 am to 5.00 pm at
New York, NY Equity Profile Report initiates a NASDAQ Active Stock Watch List adding Halozyme Therapeutics, Inc., NetApp, Inc., Infinity Pharmaceuticals, Inc. and DryShips, Inc. Halozyme Therapeutics, Inc. a biopharmaceutical company that concentrates on the development of human enzymes finished yesterday at on 5,329,593 shares traded.
Release date- 16052013- Horsham, PA,- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration has approved SIMPONI for the treatment of moderately to severely active ulcerative colitis in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral...
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. Fenofibrate Tablets, 48 mg and 145 mg, had U.S. sales of approximately $1.2 billion for the 12 months ending March 31, 2013, according to IMS Health. Currently, Mylan has 178 ANDAs pending FDA approval representing $83.1 bill
Indian pharmaceutical maker Ranbaxy will pay $500 million to North Carolina, other states and the federal government for selling generic drugs that didn't meet quality standards, Attorney General Roy Cooper announced today. North Carolina joined with other states and the federal government in an agreement in principle to settle allegations that Ran
May 17 MEYERSDALE After three drug arrests in connection with two Meyersdale- area methamphetamine labs, Somerset County authorities said they hope a strong message is being sent to drug manufacturers and dealers operating in the region. State police, in conjunction with the Somerset Single County Authority for Drug and Alcohol and Somerset Cou
By a News Reporter-Staff News Editor at Health& Medicine Week Retrophin, Inc., a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options, announced that it has named Horacio Plotkin, M.D. as Chief Medical
May 17 NASHVILLE Generic drug maker Ranbaxy will pay Tennessee $5.53 million under a $500 million national agreement that resolves claims the company sold inferior drugs and made false statements regarding how the drugs were manufactured, State Attorney General Bob Cooper announced Thursday. Tennessee joined with other states and the federal...
For several years, Teva's drug and generic versions of morning-after pills have been available to females 17 or older without a prescription. Some of Teva's quiet approach relates to the touchy subject. Some of the strategy appears related to a deal Teva managed to strike with the FDA on April 30 that would make Teva's contraceptive more accessible
PLEASANTON, Calif., May 17, 2013/ PRNewswire/ Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it has received approval from the U.S. Food and Drug Administration to market the HeartMate II Pocket Controller?, the small, smart, safe
The U.S. Army issued the following news:. For the first time in its 70- year history, the U.S. Army Institute of Surgical Research at Joint Base San Antonio-Fort Sam Houston received 510 clearance from the U.S. Food and Drug Administration for a medical device developed at the USAISR. The clearance for the Burn Navigator or Burn Resuscitation Decis
SANTA CLARA, Calif. Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June. Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions. XenoPort also is developing potential
DALLAS and NEW YORK, May 16, 2013/ PRNewswire/ ACCESS PHARMACEUTICALS, INC., an emerging biopharmaceutical company, released its first quarter ended March 31, 2013 financial results. MuGard gross revenues for the quarter ended March 31, 2013 were $1.255 million, an increase of 118% compared to the first quarter 2012 and an increase of over 20% fr
